Approximately 7, people from more than 90 countries attended the 5-day program. The conference provided insights into recent trials and therapeutic advances in the management of breast cancer. KATHERINE is an international phase 3 open-label study of 1, patients with residual breast or axillary disease after neoadjuvant chemotherapy and HER2-targeted therapy that randomized patients to receive 14 cycles of adjuvant ado-trastuzumab emtansine T-DM1 or trastuzumab.
Oncology social workers help you cope with the emotional and practical challenges of triple negative breast cancer. Learn more about counseling. Komen to offer a specialized breast care helpline.
Standard chemotherapy was recommended after surgery in patients who did not achieve a pCR; patients who received a pCR had the option of adjuvant chemotherapy. The primary endpoint was pCR, which has already been reported. Secondary endpoints included translational analyses, which have not been reported until now.
She called me on Friday evening, from the Newark airport, after a very busy week and a long day of travel to give me her insights from this meeting. That says a lot about the commitment that she has to the TNBC community. Carey is a distinguished professor of breast cancer research at the University of North Carolina Lineberger Comprehensive Cancer Center.
Give us feedback! Take our podcast listener survey. Morante, a medical oncologist at the institute.
A retrospective study evaluating the influence of time to chemotherapy on patients with triple-negative disease and its impact on survival outcome has found that patients who delayed adjuvant chemotherapy more than 30 days after surgery had a significantly higher risk for disease recurrence and death compared with patients who underwent treatment within the first 30 days following surgery. The greater the delay, the worse the outcome. According to the study results, delays in receiving adjuvant chemotherapy initiation in this high-risk group of patients should be avoided.
The event presented a balance of clinical, basic and translational research in breast cancer and was the first national meeting to include programs for patient advocates. T-DM 1 improves disease-free survival compared to trastuzumab in patients with early-stage HER2-positive breast cancer. HER2-positive breast cancer accounts for approximately 20 percent of breast cancers.
The exception to this, however, may be in patients with nonbasal-like disease. The trial enrolled patients with early triple-negative breast cancer that was node-positive and who had undergone surgery and standard chemotherapy. Node-negative disease was included if the tumor size was 1 cm or greater. Stratification factors included institution site, phenotype basal vs nonbasalprior chemotherapy regimen, and involvement of axillary lymph nodes.